• linkedin
  • Increase Font
  • Sharebar

    OCTA: Future Is bright, fast, and wide in ROP

     

    OCTA in peer-review

    A few publications have reported on the use of OCTA in young children, he recounted. Vinekar, et al., in 2016 published a report in the Journal of the American Association for Pediatric Ophthalmology and Strabismus that described the use of Optovue’s AngioVue instrument using the “flying-baby technique” in which they demonstrated hyper-reflective material corresponding to recurrent neovascularization seen on FA.

    Cross sectional optical coherence tomography angiogram of a patient with retinopathy of prematurity demonstrating choroidal and retinal flow, as well as flow above the internal limiting membrane (blue) representing extra retinal neovascularization (Images courtesy of J. Peter Campbell, MD, MPH)

    In 2017, Chen, et al., published case reports in JAMA Ophthalmology in which they used a prototype swept-source (SS-OCT) instrument that was integrated into the operating room microscope to acquire OCTA images intraoperatively for the first time in two young patients.

    “Both of these were great advances,” Dr. Campbell said. “However, neither technique is practical for widespread use in ROP screening and diagnosis. Both of these procedures have demonstrated some potential limitations of OCTA in this population.”

    The trend for retinal angiography has been toward increasing the field of view over time, Dr. Campbell added. “Many retina specialists have become used to caring for patients by relying on the ultrawide-field FA findings,” Dr. Campbell commented. “OCTA provides higher depth resolution but a more limited field of view.”

     

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';